Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | STK17B | O94768 | 12/20 | 0.45 |
| ▸ | MAP3K8 | P41279 | 7/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.45 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17268777 | 0.71 | IKBKB (0.61) | STK17BMAP3K8STK17A | |
| SCHEMBL28666644 | 0.63 | CYP2A6 (0.56) | SMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL29861035 | 0.63 | CYP2A6 (0.56) | SMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL11375539 | 0.62 | KMT2A (0.66) | SMN1; SMN2ALDH1A1L3MBTL1TDP1MEN1 | |
| SCHEMBL28674583 | 0.62 | KMT2A (0.47) | SMN1; SMN2ALDH1A1L3MBTL1TDP1MEN1 | |
| SCHEMBL6168851 | 0.60 | RAB9A (0.47) | SMN1; SMN2ALDH1A1L3MBTL1TDP1MEN1 | |
| SCHEMBL6168844 | 0.59 | MAPT (0.51) | SMN1; SMN2L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL8804837 | 0.59 | KMT2A (0.45) | SMN1; SMN2ALDH1A1L3MBTL1TDP1MEN1 | |
| SCHEMBL2933353 | 0.59 | RAB9A (0.42) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL23621610 | 0.59 | MAPT (0.50) | SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | SMN1; SMN2 2527/4885ALDH1A1 2177/4885L3MBTL1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.